These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10211913)

  • 41. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
    Montgomery SA; Locklear JC; Svedsäter H; Eriksson H
    Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
    DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM
    Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
    Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
    Bendele A; Means J; Shoufler J; Schmalz C; Hanasono G; Symanowski J; Adams E
    Drug Chem Toxicol; 1995 Feb; 18(1):61-82. PubMed ID: 7768200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.
    Roy Chengappa K; Kupfer DJ; Parepally H; John V; Basu R; Buttenfield J; Schlicht P; Houck P; Brar JS; Gershon S
    Bipolar Disord; 2007 Sep; 9(6):609-17. PubMed ID: 17845276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
    Stein DJ; Ahokas A; Jarema M; Avedisova AS; Vavrusova L; Chaban O; Gruget C; Olivier V; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2017 May; 27(5):526-537. PubMed ID: 28298261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
    Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.
    Khan A; Joyce M; Atkinson S; Eggens I; Baldytcheva I; Eriksson H
    J Clin Psychopharmacol; 2011 Aug; 31(4):418-28. PubMed ID: 21694613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorder: Systematic review and meta-analysis.
    Gale C; Glue P; Guaiana G; Coverdale J; McMurdo M; Wilkinson S
    J Psychopharmacol; 2019 May; 33(5):543-547. PubMed ID: 30676225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
    Gibiino S; Mori E; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
    Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial.
    Meibach RC; Dunner D; Wilson LG; Ishiki D; Dager SR
    J Clin Psychiatry; 1987 Sep; 48(9):355-8. PubMed ID: 3305488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH; Tiller J; Xie F; Trivedi MH
    J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial.
    Villarreal G; Hamner MB; Cañive JM; Robert S; Calais LA; Durklaski V; Zhai Y; Qualls C
    Am J Psychiatry; 2016 Dec; 173(12):1205-1212. PubMed ID: 27418378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
    Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
    J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
    Meoni P; Hackett D; Lader M
    Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.